Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
New findings from the first large, randomized clinical trial to compare chemotherapy regimens for relapsed or treatment-resistant Ewing sarcoma could help doctors and patients select treatments.
-
People with metastatic breast cancer whose tumors had low levels of HER2 protein lived longer after treatment with trastuzumab deruxtecan (Enhertu) than those treated with standard chemotherapy, results of the DESTINY-Breast04 clinical trial show.
-
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) shrank more brain tumors, kept the tumors at bay for longer, and caused fewer side effects than chemotherapy, trial results showed. The children all had glioma with a BRAF V600 mutation that could not be surgically removed or came back after surgery.
-
One dose of the HPV vaccine was highly effective in protecting young women against infection from high-risk HPV types, a study in Kenya found. A single dose would make HPV vaccines more accessible worldwide, reducing cervical cancer’s global burden.
-
Giving people with early-stage lung cancer the immunotherapy drug nivolumab (Opdivo) and chemotherapy before surgery can substantially delay the progression or return of their cancer, a large clinical trial found.
-
For some people with acute myeloid leukemia (AML) that has a mutation in the IDH1 gene, combining ivosidenib (Tibsovo) with the chemotherapy drug azacitidine may be a new treatment option, according to results from a large clinical trial.
-
After surgery for early-stage, low-risk testicular cancer, it’s safe to monitor for a recurrence using MRI scans or fewer CT scans than are currently used, according to results from a large clinical trial.
-
Adding darolutamide (Nubeqa) to ADT and docetaxel (Taxotere) can improve how long men with hormone-sensitive metastatic prostate cancer live without causing more side effects, results from the ARASENS trial show.
-
New results from a large study show that trametinib (Mekinist) is an effective treatment for low-grade serous ovarian cancer. The findings are the first strong evidence that this rare type of ovarian cancer should be treated differently from other forms of the disease.
-
Adding durvalumab (Imfinzi) to standard chemotherapy modestly extended how long people with advanced biliary tract cancer lived, results from the TOPAZ-1 trial show. The immunotherapy drug may now be the standard first-line therapy for this hard-to-treat cancer.